Literature DB >> 10680068

Cancer and aging. An evolving panorama.

L Balducci1, M Extermann.   

Abstract

This article illustrates how the nosology of cancer evolves with the patient's age. If the current trends are maintained, 70% of all neoplasms will occur in persons aged 65 years and over by the year 2020, leading to increased cancer-related morbidity among older persons. Cancer control in the older person involves chemoprevention, early diagnosis, and timely and effective treatment that entails both antineoplastic therapy and symptom management. These interventions must be individualized based on a multidimensional assessment that can predict life expectancy and treatment complications and that may evaluate the quality of life of the older person. This article suggests a number of interventions that may improve cancer control in the aged. Public education is needed to illustrate the benefits of health maintenance and early detection of cancer even among older individuals, to create realistic expectations, and to heighten awareness of early symptoms and signs of cancer. Professional education is needed to train students and practitioners in the evaluation and management of the older person. Of special interest is the current initiative of the Hartford Foundation offering combined fellowships in oncology and geriatrics and incorporating principles of geriatric medicine in medical specialty training. Prudent pharmacologic principles must be followed in managing older persons with cytotoxic chemotherapy. These principles include adjusting the dose according to the patient's renal function, using epoietin to maintain hemoglobin levels of 12 g/dL or more, and using hemopoietic growth factors in persons aged 70 years and older receiving cytotoxic chemotherapy of moderate toxicity (e.g., CHOP). To assure uniformity of data, a cooperative oncology group should formulate a geriatric package outlining a common plan for evaluating function and comorbidity. This article also suggests several important areas of research items: Molecular interactions of age and cancer Host-tumor interactions in the older tumor host Chemoprevention of cancer and aging Laboratory evaluation of aging Development of shorter forms of geriatric assessment Management of the frail cancer patients Clinical trials of tumor-specific issues.

Entities:  

Mesh:

Year:  2000        PMID: 10680068     DOI: 10.1016/s0889-8588(05)70274-4

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  26 in total

Review 1.  The role of myelopoietic growth factors in managing cancer in the elderly.

Authors:  Lodovico Balducci; Ignazio Carreca
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Senior adult oncology.

Authors:  Arti Hurria; Ilene S Browner; Harvey Jay Cohen; Crystal S Denlinger; Mollie deShazo; Martine Extermann; Apar Kishor P Ganti; Jimmie C Holland; Holly M Holmes; Mohana B Karlekar; Nancy L Keating; June McKoy; Bruno C Medeiros; Ewa Mrozek; Tracey O'Connor; Stephen H Petersdorf; Hope S Rugo; Rebecca A Silliman; William P Tew; Louise C Walter; Alva B Weir; Tanya Wildes
Journal:  J Natl Compr Canc Netw       Date:  2012-02       Impact factor: 11.908

Review 3.  The aging kidney: a review--part II.

Authors:  Fred G Silva
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

4.  Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA.

Authors:  Attilio Olivieri; Guido Gini; Caterina Bocci; Mauro Montanari; Silvia Trappolini; Jacopo Olivieri; Marino Brunori; Massimo Catarini; Barbara Guiducci; Alessandro Isidori; Francesco Alesiani; Luciano Giuliodori; Massimo Marcellini; Giuseppe Visani; Antonella Poloni; Pietro Leoni
Journal:  Oncologist       Date:  2012-04-24

5.  Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries.

Authors:  Supriya Gupta Mohile; Ying Xian; William Dale; Susan G Fisher; Miriam Rodin; Gary R Morrow; Alfred Neugut; William Hall
Journal:  J Natl Cancer Inst       Date:  2009-07-28       Impact factor: 13.506

6.  Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma.

Authors:  Yujin Kobayashi; Katsuhiro Miura; Atsuko Hojo; Yoshihiro Hatta; Toshitake Tanaka; Daisuke Kurita; Noriyoshi Iriyama; Sumiko Kobayashi; Jin Takeuchi
Journal:  J Cancer Res Clin Oncol       Date:  2011-01-11       Impact factor: 4.553

7.  Association of multidimensional comorbidities with survival, toxicity, and unplanned hospitalizations in older adults with metastatic colorectal cancer treated with chemotherapy.

Authors:  Ki Hyang Kim; Jae Jin Lee; Jongphil Kim; Jun-Min Zhou; Fabio Gomes; Marina Sehovic; Martine Extermann
Journal:  J Geriatr Oncol       Date:  2019-02-11       Impact factor: 3.599

8.  Interplay between aging, lung inflammation/remodeling, and fibronectin EDA in lung cancer progression.

Authors:  John C Greenwell; Edilson Torres-Gonzalez; Jeffrey D Ritzenthaler; Jesse Roman
Journal:  Cancer Biol Ther       Date:  2020-11-23       Impact factor: 4.742

9.  Non-invasive brain stimulation: enhancing motor and cognitive functions in healthy old subjects.

Authors:  Maximo Zimerman; Friedhelm C Hummel
Journal:  Front Aging Neurosci       Date:  2010-12-01       Impact factor: 5.750

10.  Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients.

Authors:  Alfredo Carrato; Luis Paz-Ares Rodríguez; Alvaro Rodríguez Lescure; Ana M Casas Fernández de Tejerina; Eduardo Díaz Rubio García; Pedro Pérez Segura; Manuel Constenla Figueiras; Rocío García Carbonero; José Gómez Codina; Ana Lluch Hernández; José Pablo Maroto Rey; Miguel Martín Jiménez; José Ignacio Mayordomo Cámara; José Andrés Moreno Nogueira; Antonio Rueda Domínguez
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.